Movement disorders clinical practice · 2026
Depression in Parkinson's Disease: Real-World Prescribing Patterns and Treatment Dynamics from a Nationwide Greek Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karageorgiou Vasilios, Skapinakis Petros, Michopoulos Ioannis, Mitrou Panagiota, Thireos Eleftherios, Gournellis Rossetos
Аннотация
BACKGROUND: Depression in Parkinson's disease (PD-DD) is common, but little is known for outcomes after antidepressants are started.
OBJECTIVES: We examine prescribing patterns and treatment trajectories for depression in Parkinson's disease (PD) in a Greek nationwide cohort (IDYKA) of 28,370 PD-DD patients and 660,504 DD patients without PD.
METHODS: Target trial emulation with propensity score weighting comparing SSRIs, non-SSRI antidepressants, atypical antipsychotics (AAPs), and benzodiazepines on discontinuation and switching/augmentation.
RESULTS: The PD-DD association (pooled OR 8.37, 95% CI 5.02-13.98) is age-dependent in both sexes. Clinicians favored sedative agents, particularly mirtazapine (age- and gender-adjusted OR [aOR] 1.26, 95% CI 1.22-1.30), duloxetine (1.41, 1.36-1.48), and quetiapine (1.33, 1.28-1.38). AAP were less commonly discontinued compared to SSRIs (HR 0.838 [0.771, 0.911]). Non-SSRI ADs were associated with higher switch/augmentation rates (1.155 [1.058, 1.240]).
CONCLUSIONS: In PD depression, AAP outlast SSRIs in real-world persistence and non-SSRIs are more commonly switched or augmented.
OBJECTIVES: We examine prescribing patterns and treatment trajectories for depression in Parkinson's disease (PD) in a Greek nationwide cohort (IDYKA) of 28,370 PD-DD patients and 660,504 DD patients without PD.
METHODS: Target trial emulation with propensity score weighting comparing SSRIs, non-SSRI antidepressants, atypical antipsychotics (AAPs), and benzodiazepines on discontinuation and switching/augmentation.
RESULTS: The PD-DD association (pooled OR 8.37, 95% CI 5.02-13.98) is age-dependent in both sexes. Clinicians favored sedative agents, particularly mirtazapine (age- and gender-adjusted OR [aOR] 1.26, 95% CI 1.22-1.30), duloxetine (1.41, 1.36-1.48), and quetiapine (1.33, 1.28-1.38). AAP were less commonly discontinued compared to SSRIs (HR 0.838 [0.771, 0.911]). Non-SSRI ADs were associated with higher switch/augmentation rates (1.155 [1.058, 1.240]).
CONCLUSIONS: In PD depression, AAP outlast SSRIs in real-world persistence and non-SSRIs are more commonly switched or augmented.